Related Experiment Video

Updated: Sep 26, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell

James J Kobie1, Rita S Wu, Robert A Kurt

  • 1Department of Microbiology and Immunology, University of Arizona, Tucson, Arizona 85724, USA.

Cancer Research
|April 19, 2003
PubMed

Insights

Neutralizing transforming growth factor beta (TGF-beta) enhances dendritic cell (DC) vaccine effectiveness against established tumors. This approach improved tumor inhibition and led to complete tumor regression in 40% of mice.

Area of Science:

  • Immunology
  • Cancer Biology
  • Vaccinology

Background:

  • Dendritic cell (DC)-based vaccines show limited efficacy against established tumors.
  • The tumor microenvironment contains factors, like transforming growth factor beta (TGF-beta), that impair DC function.
  • TGF-beta inhibits antigen presentation, T-lymphocyte stimulation, and DC migration.

Purpose of the Study:

  • To evaluate the impact of TGF-beta on DC immunostimulatory activities.
  • To assess the efficacy of TGF-beta neutralization in combination with DC vaccines against established tumors.

Main Methods:

  • In vitro assessment of TGF-beta's effect on DC functions.
  • In vivo studies using 4T1 murine mammary tumor model.
  • Administration of DC vaccines combined with a TGF-beta-neutralizing antibody (2G7).
  • Evaluation of tumors transduced with antisense TGF-beta transgene (4T1-asT).

Main Results:

  • TGF-beta exposure significantly inhibited DC antigen presentation, T-lymphocyte stimulation, and lymph node migration.
  • Neutralization of TGF-beta with antibody 2G7 enhanced DC vaccine efficacy in inhibiting 4T1 tumor growth.
  • Combination therapy (DC vaccine + 2G7) in 4T1-asT tumors resulted in tumor growth inhibition and 40% complete tumor regression.

Conclusions:

  • TGF-beta neutralization is a promising strategy to overcome the immunosuppressive tumor microenvironment.
  • Combining TGF-beta neutralization with DC vaccines significantly improves anti-tumor immunity.
  • This approach holds potential for enhancing the clinical efficacy of DC-based cancer vaccines.

More Related Videos

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...